Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2007

01.01.2007 | Original article

Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET

verfasst von: Katja Havu-Aurén, Johanna Kiiski, Kaisa Lehtiö, Olli Eskola, Martti Kulvik, Ville Vuorinen, Vesa Oikonen, Jyrki Vähätalo, Juha Jääskeläinen, Heikki Minn

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Meningiomas and schwannomas associated with neurofibromatosis 2 (NF2) are difficult to control by microsurgery and stereotactic radiotherapy alone. Boron neutron capture therapy (BNCT) is a chemically targeted form of radiotherapy requiring increased concentration of boron-10 in tumour tissue. PET with the boron carrier 4-borono-2-[18F]fluoro-L-phenylalanine ([18F]FBPA) allows investigation of whether 4-borono-L-phenylalanine (BPA) concentrates in NF2 tumours, which would make BNCT feasible.

Methods

We studied dynamic uptake of [18F]FBPA in intracranial meningiomas (n=4) and schwannomas (n=6) of five sporadic and five NF2 patients. Tracer input function and cerebral blood volume were measured. [18F]FBPA uptake in tumour and brain was assessed with a three-compartmental model and graphical analysis. These, together with standardised uptake values (SUVs), were used to define tumour-to-brain [18F]FBPA tissue activity gradients.

Results

Model fits with three parameters K 1 (transport), k 2 (reverse transport) and k 3 (intracellular metabolism) were found to best illustrate [18F]FBPA uptake kinetics. Maximum SUV was two- to fourfold higher in tumour as compared with normal brain and independent of NF2 status. The increased uptake was due to higher transport of [18F]FBPA in tumour. In multiple-time graphical analysis (MTGA, Gjedde-Patlak plot) the tumour-to-brain [18F]FBPA influx constant (K i -MTGA) ratios varied between 1.8 and 5.4 in NF2-associated tumours while in sporadic tumours the ratio was 1–1.4.

Conclusion

[18F]FBPA PET offers a viable means to evaluate BPA uptake in meningiomas and schwannomas in NF2. Based on our results on tumour uptake of [18F]FBPA, some of these benign neoplasms may be amenable to BNCT.
Literatur
1.
Zurück zum Zitat Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043–1050PubMedCrossRef Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043–1050PubMedCrossRef
2.
Zurück zum Zitat Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515–521PubMedCrossRef Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515–521PubMedCrossRef
3.
Zurück zum Zitat Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791–800PubMedCrossRef Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791–800PubMedCrossRef
4.
Zurück zum Zitat Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51–57PubMedCrossRef Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51–57PubMedCrossRef
5.
Zurück zum Zitat Louis DN, Stemmer-Rachamimov AO, Wiestler OD. Neurofibromatosis type 2. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 219–222 Louis DN, Stemmer-Rachamimov AO, Wiestler OD. Neurofibromatosis type 2. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 219–222
6.
Zurück zum Zitat Louis DN, Scheithauer BW, Budka H. Meningeomas. In: Kleihues P, Cavanee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 176–184 Louis DN, Scheithauer BW, Budka H. Meningeomas. In: Kleihues P, Cavanee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 176–184
7.
Zurück zum Zitat Woodruff JM, Kourea HP, Louis DN. Schwannoma. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 164–171 Woodruff JM, Kourea HP, Louis DN. Schwannoma. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000; p. 164–171
8.
Zurück zum Zitat Subach BR, Kondziolka D, Lundsford LD, Bissonette DJ, Flickinger JC, Maitz AH. Stereotactic radiosurgery in the management of acoustic neurinomas associated with neurofibromatosis type 2. J Neurosurg 1999;90:815–822PubMedCrossRef Subach BR, Kondziolka D, Lundsford LD, Bissonette DJ, Flickinger JC, Maitz AH. Stereotactic radiosurgery in the management of acoustic neurinomas associated with neurofibromatosis type 2. J Neurosurg 1999;90:815–822PubMedCrossRef
9.
Zurück zum Zitat Barth RF, Soloway AH, Goodman JH, Gahbauer RA, Gupta N, Blue TE, et al. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality. Neurosurgery 1999;44:433–451PubMedCrossRef Barth RF, Soloway AH, Goodman JH, Gahbauer RA, Gupta N, Blue TE, et al. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality. Neurosurgery 1999;44:433–451PubMedCrossRef
10.
Zurück zum Zitat Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, et al. Treatment of malignant melanoma by single neutron capture treatment with melanoma-seeking 10B compound. Lancet 1989;2:388–389PubMedCrossRef Mishima Y, Honda C, Ichihashi M, Obara H, Hiratsuka J, Fukuda H, et al. Treatment of malignant melanoma by single neutron capture treatment with melanoma-seeking 10B compound. Lancet 1989;2:388–389PubMedCrossRef
11.
Zurück zum Zitat Kouri M, Kankaanranta L, Seppälä T, Tervo L, Rasilainen M, Minn H, et al. Undifferentiated sinonasal carcinoma may respond to single-fraction boron neutron capture therapy. Radiother Oncol 2004;72:83–85PubMedCrossRef Kouri M, Kankaanranta L, Seppälä T, Tervo L, Rasilainen M, Minn H, et al. Undifferentiated sinonasal carcinoma may respond to single-fraction boron neutron capture therapy. Radiother Oncol 2004;72:83–85PubMedCrossRef
12.
Zurück zum Zitat Pinelli T, Zonta A, Altieri S, et al. From the first idea to the application to the human liver. In: Sauerwein W, Moss R, Witting A, editors. Research and development in neutron capture therapy. Bologna: Monduzzi Editore; 2002; p. 1065–1072 Pinelli T, Zonta A, Altieri S, et al. From the first idea to the application to the human liver. In: Sauerwein W, Moss R, Witting A, editors. Research and development in neutron capture therapy. Bologna: Monduzzi Editore; 2002; p. 1065–1072
13.
Zurück zum Zitat Joensuu H, Kankaanranta L, Seppälä T, Auterinen I, Kallio M, Kulvik M, et al. Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neuro-Oncol 2003;62:123–134 Joensuu H, Kankaanranta L, Seppälä T, Auterinen I, Kallio M, Kulvik M, et al. Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neuro-Oncol 2003;62:123–134
14.
Zurück zum Zitat Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 1998;39:325–333PubMed Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 1998;39:325–333PubMed
15.
Zurück zum Zitat Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high grade gliomas: part I. Clin Cancer Res 1998;4:1825–1832PubMed Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high grade gliomas: part I. Clin Cancer Res 1998;4:1825–1832PubMed
16.
Zurück zum Zitat Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high grade gliomas: part II, Clin Cancer Res 1998;4:1833–1841PubMed Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high grade gliomas: part II, Clin Cancer Res 1998;4:1833–1841PubMed
17.
Zurück zum Zitat Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CP, Roberts TG, et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J Nucl Med 1997;38:1762–1767PubMed Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CP, Roberts TG, et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J Nucl Med 1997;38:1762–1767PubMed
18.
Zurück zum Zitat Ishiwata K, Shiono M, Kubota K, Yoshino K, Hatazawa J, Ido T, et al. A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumor tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine. Melanoma Res 1992;2:171–179PubMedCrossRef Ishiwata K, Shiono M, Kubota K, Yoshino K, Hatazawa J, Ido T, et al. A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumor tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine. Melanoma Res 1992;2:171–179PubMedCrossRef
19.
Zurück zum Zitat Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997;24:677–683PubMedCrossRef Bergman J, Solin O. Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997;24:677–683PubMedCrossRef
20.
Zurück zum Zitat Vähätalo JK, Eskola O, Bergman J, Forsback S, Lehikoinen P, Jääskeläinen J, et al. Synthesis of 4-dihydroxyboryl-2-[18F]fluorophenylalanine with relatively high-specific activity. J Labelled Cpd Radiopharm 2002;45:697–704CrossRef Vähätalo JK, Eskola O, Bergman J, Forsback S, Lehikoinen P, Jääskeläinen J, et al. Synthesis of 4-dihydroxyboryl-2-[18F]fluorophenylalanine with relatively high-specific activity. J Labelled Cpd Radiopharm 2002;45:697–704CrossRef
21.
Zurück zum Zitat Kaisti KK, Långsjö JW, Aalto S, Oikonen V, Sipila H, Teras M, et al. Effects of seroflurane, propofol and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption and blood volume in humans. Anesthesiology 2003;99:603–613PubMedCrossRef Kaisti KK, Långsjö JW, Aalto S, Oikonen V, Sipila H, Teras M, et al. Effects of seroflurane, propofol and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption and blood volume in humans. Anesthesiology 2003;99:603–613PubMedCrossRef
22.
Zurück zum Zitat Pelizzari CA, Chen GT, Spelbring DR, Weichselbaum RR, Chen CT. Accurate three-dimensional registration on CT, PET and/or MR images of the brain. J Comput Assist Tomogr 1989;13:20–26PubMedCrossRef Pelizzari CA, Chen GT, Spelbring DR, Weichselbaum RR, Chen CT. Accurate three-dimensional registration on CT, PET and/or MR images of the brain. J Comput Assist Tomogr 1989;13:20–26PubMedCrossRef
23.
Zurück zum Zitat Witting A, Sauerwein WA, Coderre JA. Mechanisms of transport of borono-phenylalanine through the cell membrane. Radiat Res 2000;153:173–180CrossRef Witting A, Sauerwein WA, Coderre JA. Mechanisms of transport of borono-phenylalanine through the cell membrane. Radiat Res 2000;153:173–180CrossRef
24.
25.
Zurück zum Zitat Jager PL, Vaalburg W, Pruim J, de Vries EGE, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–445PubMed Jager PL, Vaalburg W, Pruim J, de Vries EGE, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–445PubMed
26.
Zurück zum Zitat Otsuka S, Tamiya T, Ono Y, Michiue H, Kurozumi K, Daido S, et al. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neuro-Oncol 2004;70(3):349–357CrossRef Otsuka S, Tamiya T, Ono Y, Michiue H, Kurozumi K, Daido S, et al. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neuro-Oncol 2004;70(3):349–357CrossRef
Metadaten
Titel
Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET
verfasst von
Katja Havu-Aurén
Johanna Kiiski
Kaisa Lehtiö
Olli Eskola
Martti Kulvik
Ville Vuorinen
Vesa Oikonen
Jyrki Vähätalo
Juha Jääskeläinen
Heikki Minn
Publikationsdatum
01.01.2007
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0154-y

Weitere Artikel der Ausgabe 1/2007

European Journal of Nuclear Medicine and Molecular Imaging 1/2007 Zur Ausgabe